Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial

The rapid descent continues for hydroxychloroquine as hope for a cure for COVID-19. On Monday, pharmaceutical giant Novartis (NYSE:NVS) announced that it is stopping the sponsored clinical trial it was conducting on the treatment of COVID-19 with the drug.